Eli Lilly and Company (Lilly) has agreed to acquire SiteOne Therapeutics Inc., a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders. The transaction includes STC-004, a Phase 2 ready Nav1.8 inhibitor being studied for the treatment of pain, which may represent a next-generation, non-opioid treatment for chronic pain. “The global burden of chronic pain continues to increase, and an effectiv...